Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA1007)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 September 2024
Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA962)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 March 2024
Ovarian cancer: identifying and managing familial and genetic risk (NG241)Product type:GuidanceProgramme:NICE guidelinePublished: 21 March 2024
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 October 2024
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer ID6442Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC